Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, emerging HER2-targeting drugs in development are forecast to enter the market, while current HER2-targeting agents will see their sales change as a result of competition, label expansions, biosimilars entry, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna), PD-1-targeting agents (Roche/Genentech/Chugai’s Tecentriq), and PI3K inhibitors (Novartis’s Piqray), as well as anticipated entry of agents within these drug classes will provide more diverse and much needed treatment options, especially for triple-negative breast cancer.
Questions answered
- What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as the CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, and PI3K inhibitors in the various subpopulations of breast cancer?
- What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
- What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?
Contents Highlights
Geographies: United States, EU5, Japan
Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research
Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2028, segmented by brands/generics and market-relevant drug-treatable populations
Emerging Therapies: Phase III/PR: 15 drugs; coverage of select Phase I and II products
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
